- Home
- SPRY vs BCSF Comparison
SPRY vs BCSF Comparison
Compare SPRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- BCSF
- Stock Information
- Founded
- SPRY 2015
- BCSF 2015
- Country
- SPRY United States
- BCSF United States
- Employees
- SPRY N/A
- BCSF N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- SPRY Health Care
- BCSF Finance
- Exchange
- SPRY Nasdaq
- BCSF Nasdaq
- Market Cap
- SPRY 1.1B
- BCSF 1.1B
- IPO Year
- SPRY N/A
- BCSF 2018
- Fundamental
- Price
- SPRY $14.08
- BCSF $17.79
- Analyst Decision
- SPRY Strong Buy
- BCSF Hold
- Analyst Count
- SPRY 4
- BCSF 4
- Target Price
- SPRY $26.00
- BCSF $16.75
- AVG Volume (30 Days)
- SPRY 1.4M
- BCSF 200.9K
- Earning Date
- SPRY 03-20-2025
- BCSF 02-25-2025
- Dividend Yield
- SPRY N/A
- BCSF 10.11%
- EPS Growth
- SPRY N/A
- BCSF N/A
- EPS
- SPRY N/A
- BCSF 1.99
- Revenue
- SPRY $2,568,000.00
- BCSF $294,257,000.00
- Revenue This Year
- SPRY $66,750.00
- BCSF N/A
- Revenue Next Year
- SPRY $508.63
- BCSF N/A
- P/E Ratio
- SPRY N/A
- BCSF $8.95
- Revenue Growth
- SPRY 8460.00
- BCSF 3.17
- 52 Week Low
- SPRY $6.13
- BCSF $14.78
- 52 Week High
- SPRY $18.51
- BCSF $17.97
- Technical
- Relative Strength Index (RSI)
- SPRY 71.29
- BCSF 63.34
- Support Level
- SPRY $11.00
- BCSF $16.79
- Resistance Level
- SPRY $12.48
- BCSF $17.88
- Average True Range (ATR)
- SPRY 0.85
- BCSF 0.27
- MACD
- SPRY 0.42
- BCSF 0.04
- Stochastic Oscillator
- SPRY 95.43
- BCSF 91.74
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.